Company intelligence / Profile preview

Credo Diagnostics Biomedical Pte. Ltd.

Ownership: Private
Employees: ~42
Development stage: Commercial

Overview

Credo Diagnostics has developed and commercialized rapid molecular diagnostic platforms for point-of-care testing. Their VitaSIRO solo™ system delivers real-time PCR results in about 20 minutes for a range of infectious diseases and genetic markers. The company’s assays are CE-marked and used internationally; clinical performance data is available for their COVID‑19/Flu/RSV multiplex test.

Therapeutic areas: OtherGastroenterologyInfectious Diseases
Modalities: DeviceMolecular diagnostic platform
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Credo Diagnostics Biomedical Pte. Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Credo Diagnostics Biomedical Pte. Ltd..

Explore the full profile